{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:16:06Z","timestamp":1791234966505,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","neuropeptidesjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.npep.2016.01.002","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T00:32:59Z","timestamp":1452645179000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Chromogranin A and other enteroendocrine markers in inflammatory bowel disease"],"prefix":"10.1016","volume":"58","author":[{"given":"Sara","family":"Massironi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavalcoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.npep.2016.01.002_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2003.50141","article-title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","volume":"124","author":"Abad","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/156802606775270288","article-title":"Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP","volume":"6","author":"Abad","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.npep.2016.01.002_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0016-5085(86)90936-4","article-title":"Peptide YY abnormalities in gastrointestinal diseases","volume":"90","author":"Adrian","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0020","first-page":"1","article-title":"Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon","volume":"8","author":"Ahonen","year":"1976","journal-title":"Ann. Clin. Res."},{"key":"10.1016\/j.npep.2016.01.002_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000135623","article-title":"Vasoactive intestinal peptide as a healing mediator in Crohn's disease","volume":"15","author":"Arranz","year":"2008","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.npep.2016.01.002_bb0030","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.peptides.2008.01.019","article-title":"VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4","volume":"29","author":"Arranz","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0035","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s10620-007-0113-x","article-title":"Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status","volume":"53","author":"Ates","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.peptides.2006.07.029","article-title":"A role for neuropeptide Y (NPY) in phagocytosis: implications for innate and adaptive immunity","volume":"28","author":"Bedoui","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0045","doi-asserted-by":"crossref","first-page":"G1770","DOI":"10.1152\/ajpgi.00249.2006","article-title":"Enteroendocrine cells express functional Toll-like receptors","volume":"292","author":"Bogunovic","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.npep.2016.01.002_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.gastro.2012.10.003","article-title":"Brain-gut interactions in inflammatory bowel disease","volume":"144","author":"Bonaz","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0167-0115(93)90146-Y","article-title":"Peptide YY in the mammalian pancreas: immunocytochemical localization and immunochemical characterization","volume":"43","author":"B\u00f6ttcher","year":"1993","journal-title":"Regul. Pept."},{"key":"10.1016\/j.npep.2016.01.002_bb0060","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00140.2004","article-title":"Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation","volume":"288","author":"Brun","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.npep.2016.01.002_bb0065","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.coph.2013.09.008","article-title":"Gut microbiota, enteroendocrine functions and metabolism","volume":"13","author":"Cani","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.npep.2016.01.002_bb0070","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0021-9258(19)41780-8","article-title":"The amino acid sequence of a hypothalamic peptide, neurotensin","volume":"250","author":"Carraway","year":"1975","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.npep.2016.01.002_bb0075","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1172\/JCI4217","article-title":"Neurotensin is proinflammatory neuropeptide in colonic inflammation","volume":"103","author":"Castagliuolo","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.npep.2016.01.002_bb0080","doi-asserted-by":"crossref","first-page":"e3304","DOI":"10.1371\/journal.pone.0003304","article-title":"Targeted deletion of neuropeptide Y (NPY) modulates experimental colitis","volume":"3","author":"Chandrasekharan","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.npep.2016.01.002_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5009\/gnl.2013.7.5.505","article-title":"Role of ghrelin in the pathophysiology of gastrointestinal disease","volume":"7","author":"Cheung","year":"2013","journal-title":"Gut Liver"},{"key":"10.1016\/j.npep.2016.01.002_bb0090","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0016-5085(96)70034-3","article-title":"The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders","volume":"111","author":"Collins","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0095","first-page":"G167","article-title":"Neuroimmune signaling in regulation of intestinal ion transport","volume":"266","author":"Cooke","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.npep.2016.01.002_bb0100","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.2174\/092986712802429975","article-title":"Chromogranin A and the endothelial barrier function","volume":"19","author":"Corti","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.npep.2016.01.002_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.autneu.2006.10.005","article-title":"Neuropeptide Y receptors; antisecretory control of intestinal epithelial function","volume":"133","author":"Cox","year":"2007","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.npep.2016.01.002_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.peptides.2006.07.023","article-title":"Peptide YY: a neuroendocrine neighbor of note","volume":"28","author":"Cox","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0115","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EC-14-0027","article-title":"Biological function and clinical relevance of chromogranin A and derived peptides","volume":"3","author":"D'amico","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.npep.2016.01.002_bb0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0014-5793(96)01346-4","article-title":"Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists","volume":"399","author":"Derocq","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.npep.2016.01.002_bb0125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1196\/annals.1351.041","article-title":"Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis","volume":"1069","author":"Di Comite","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.0608358","article-title":"Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation","volume":"85","author":"Di Comite","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.npep.2016.01.002_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/ard.2007.086587","article-title":"High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment","volume":"68","author":"Di Comite","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1172\/JCI200421134","article-title":"Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells","volume":"114","author":"Dixit","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.npep.2016.01.002_bb0145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/jcp.39.8.913","article-title":"Chronic ulcerative colitis complicated by atypical carcinoid tumour","volume":"39","author":"Dodd","year":"1986","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.npep.2016.01.002_bb0150","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/BF01537105","article-title":"Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease","volume":"34","author":"Duffy","year":"1989","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0155","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1210\/en.2012-1595","article-title":"A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin","volume":"153","author":"Egerod","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.npep.2016.01.002_bb0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/icb.1993.13","article-title":"In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin","volume":"71","author":"Eglezos","year":"1993","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.npep.2016.01.002_bb0165","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/nmo.12703","article-title":"Immunomodulatory effect of ghrelin in the intestinal mucosa","volume":"27","author":"Eissa","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.npep.2016.01.002_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0196-9781(01)00601-5","article-title":"Distribution of pancreatic polypeptide and peptide YY","volume":"23","author":"Ekblad","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gut.34.2.264","article-title":"Octreotide effectively decreases mucosal damage in experimental colitis","volume":"34","author":"Eliakim","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.npep.2016.01.002_bb0180","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0196-9781(90)90002-M","article-title":"Gastrointestinal neuropeptides suppress human colonic lamina propria lymphocyte DNA synthesis","volume":"11","author":"Elitsur","year":"1990","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0185","article-title":"The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD)","author":"El-Salhy","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2796.1997.00237.x","article-title":"Colonic endocrine cells in inflammatory bowel disease","volume":"242","author":"El-Salhy","year":"1997","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.npep.2016.01.002_bb0195","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.coph.2013.09.018","article-title":"Enteroendocrine cell types revisited","volume":"13","author":"Engelstoft","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.npep.2016.01.002_bb0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0165-5728(91)90042-6","article-title":"Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation","volume":"31","author":"Fais","year":"1991","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0205","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nrendo.2010.93","article-title":"Bowels control brain: gut hormones and obesity","volume":"6","author":"Field","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.npep.2016.01.002_bb0210","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/mi.2014.124","article-title":"Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease","volume":"8","author":"Friedrich","year":"2015","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0215","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0196-9781(00)00313-2","article-title":"Peptidergic regulation of gastrointestinal motility in rodents","volume":"21","author":"Fujimiya","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0220","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11481-006-9044-0","article-title":"A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells","volume":"1","author":"Ganea","year":"2006","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.npep.2016.01.002_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MED.0b013e32835bc703","article-title":"5-Hydroxytryptamine (serotonin) in the gastrointestinal tract","volume":"20","author":"Gershon","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.npep.2016.01.002_bb0230","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2009.08.041","article-title":"Serotonin has a key role in pathogenesis of experimental colitis","volume":"137","author":"Ghia","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0235","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.4049\/jimmunol.133.6.3255","article-title":"Inhibition by somatostatin of the release of mediators from human basophils and rat leukemic basophils","volume":"133","author":"Goetzl","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1196\/annals.1418.008","article-title":"Diverse mechanisms and consequences of immunoadoption of neuromediator systems","volume":"1144","author":"Goetzl","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0245","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1053\/j.gastro.2006.01.041","article-title":"Therapeutic action of ghrelin in a mouse model of colitis","volume":"130","author":"Gonzalez-Rey","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2007.078519","article-title":"Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy","volume":"66","author":"Gonzalez-Rey","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0255","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.3748\/wjg.15.4193","article-title":"Neuroendocrine carcinomas arising in ulcerative colitis: coincidences or possible correlations?","volume":"15","author":"Grassia","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.npep.2016.01.002_bb0260","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3748\/wjg.v19.i28.4504","article-title":"Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia","volume":"19","author":"Gui","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.npep.2016.01.002_bb0265","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1210\/en.2011-2170","article-title":"Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry","volume":"153","author":"Habib","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.npep.2016.01.002_bb0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.regpep.2009.09.009","article-title":"Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions","volume":"165","author":"Helle","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.npep.2016.01.002_bb0275","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00018-007-7254-0","article-title":"The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties","volume":"64","author":"Helle","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-5728(96)00118-X","article-title":"Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects","volume":"71","author":"Hernanz","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0285","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1248\/yakushi.128.1347","article-title":"Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone","volume":"128","author":"Hirotani","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.npep.2016.01.002_bb0290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.npep.2012.08.005","article-title":"Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis","volume":"46","author":"Holzer","year":"2012","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0016-5085(91)90007-8","article-title":"Effect of neuropeptide Y on jejunal water and ion transport in humans","volume":"101","author":"Holzer-Petsche","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1074\/jbc.M205366200","article-title":"Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing","volume":"278","author":"Hosoda","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.npep.2016.01.002_bb0305","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ibd.20477","article-title":"Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease","volume":"14","author":"Hosomi","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-3565(25)25061-3","article-title":"Effect of neuropeptide Y on ion transport by the rabbit ileum","volume":"238","author":"Hubel","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.npep.2016.01.002_bb0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/01.MIB.0000200345.38837.46","article-title":"Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease","volume":"12","author":"Karmiris","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0320","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000097187","article-title":"Substance-P-mediated intestinal inflammation: inhibitory effects of CP 96,345 and SMS 201-995","volume":"1","author":"Kataeva","year":"1994","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.npep.2016.01.002_bb9000","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2249.2010.04150.x","article-title":"Gut hormones: emerging role in immune activation and inflammation","volume":"161","author":"Khan","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0325","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2982.2008.01210.x","article-title":"IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease","volume":"21","author":"Kidd","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.npep.2016.01.002_bb0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gut.2008.155341","article-title":"Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice","volume":"58","author":"Kokkotou","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.npep.2016.01.002_bb0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yfrne.2004.03.002","article-title":"Ghrelin\u2014a hormone with multiple functions","volume":"25","author":"Korbonits","year":"2004","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.npep.2016.01.002_bb0340","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0016-5085(92)90762-N","article-title":"Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease","volume":"102","author":"Kubota","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.npep.2016.01.002_bb0345","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000110636","article-title":"Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation","volume":"14","author":"Leceta","year":"2006","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.npep.2016.01.002_bb0350","first-page":"2153","article-title":"Somatostatin regulates tight junction proteins expression in colitis mice","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.npep.2016.01.002_bb0355","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2982.2005.00673.x","article-title":"Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis","volume":"17","author":"Linden","year":"2005","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.npep.2016.01.002_bb0360","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.102.034702","article-title":"Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease","volume":"302","author":"Liu","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.npep.2016.01.002_bb0365","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1023\/A:1013256629600","article-title":"Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease","volume":"47","author":"Magro","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0162-3109(89)90007-6","article-title":"Short-term somatostatin infusion affects T lymphocyte responsiveness in humans","volume":"17","author":"Malec","year":"1989","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.npep.2016.01.002_bb0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1749-6632.1991.tb33114.x","article-title":"Substance P and the inflammatory and immune response","volume":"632","author":"Mantyh","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0380","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MOG.0b013e328331b69e","article-title":"Neuropeptides and inflammatory bowel disease","volume":"25","author":"Margolis","year":"2009","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.npep.2016.01.002_bb0385","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jcp.56.12.963","article-title":"Multiple microcarcinoids in a patient with long standing ulcerative colitis","volume":"56","author":"Matsumoto","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.npep.2016.01.002_bb0390","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coph.2004.06.007","article-title":"Peptide YY and appetite control","volume":"4","author":"McGowan","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.npep.2016.01.002_bb0395","series-title":"Textbook of Gastroenterology","first-page":"56","article-title":"Gastrointestinal hormones and receptors","author":"Miller","year":"2009"},{"key":"10.1016\/j.npep.2016.01.002_bb0400","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/1097-0142(19821215)50:12<2920::AID-CNCR2820501235>3.0.CO;2-N","article-title":"Argyrophilic cell hyperplasia and an atypical carcinoid tumor in chronic ulcerative colitis","volume":"50","author":"Miller","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.npep.2016.01.002_bb0405","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cgh.2007.02.013","article-title":"Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission","volume":"5","author":"Minderhoud","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.npep.2016.01.002_bb9005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ibd.21096","article-title":"Plasma chromogranin A in patients with inflammatory bowel disease: a possible explanation","volume":"16","author":"Moran","year":"2010","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.physbeh.2011.02.005","article-title":"Intestinal feedback signaling and satiety","volume":"105","author":"Moran","year":"2011","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.npep.2016.01.002_bb0415","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.crohns.2012.01.013","article-title":"Enteroendocrine cells in terminal ileal Crohn's disease","volume":"6","author":"Moran","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.npep.2016.01.002_bb0420","first-page":"169","article-title":"Involvement of 5HT3 receptors in anti-inflammatory effects of Tropisetron on experimental TNBS-induced colitis in rat","volume":"3","author":"Motavallian","year":"2013","journal-title":"Bioimpacts"},{"key":"10.1016\/j.npep.2016.01.002_bb0425","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2362.2009.02102.x","article-title":"Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats","volume":"39","author":"Mousavizadeh","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.npep.2016.01.002_bb0430","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2006-0028","article-title":"Gut peptides in the regulation of food intake and energy homeostasis","volume":"27","author":"Murphy","year":"2006","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.npep.2016.01.002_bb0435","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0014-5793(02)02981-2","article-title":"Cytoskeleton-related trafficking of the EAAC1 glutamate transporter after activation of the G (q\/11)-coupled neurotensin receptor NTS1","volume":"523","author":"Najimi","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.npep.2016.01.002_bb0440","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2249.2005.02673.x","article-title":"Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis","volume":"139","author":"Newman","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0445","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jcp.20061","article-title":"The role of substance P in inflammatory disease","volume":"201","author":"O'Connor","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.npep.2016.01.002_bb0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/gut.25.1.57","article-title":"Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease","volume":"25","author":"O'Morain","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.npep.2016.01.002_bb0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s004180050445","article-title":"Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate","volume":"112","author":"Oshima","year":"1999","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.npep.2016.01.002_bb0460","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1476-5381.2011.01326.x","article-title":"Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y","volume":"163","author":"Painsipp","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.npep.2016.01.002_bb0465","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/endo-109-6-1943","article-title":"Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat","volume":"109","author":"Patel","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.npep.2016.01.002_bb0470","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0006-291X(85)91401-9","article-title":"Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro","volume":"129","author":"Pawlikowski","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.npep.2016.01.002_bb0475","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0008-8749(84)90117-5","article-title":"Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts","volume":"84","author":"Payan","year":"1984","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-0115(83)90281-1","article-title":"Distribution and characterisation of immunoreactive somatostatin in human gastrointestinal tract","volume":"7","author":"Penman","year":"1983","journal-title":"Regul. Pept."},{"key":"10.1016\/j.npep.2016.01.002_bb0485","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/gut.2005.079483","article-title":"Circulating ghrelin levels in patients with inflammatory bowel disease","volume":"55","author":"Peracchi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.npep.2016.01.002_bb0490","first-page":"62","article-title":"Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis","volume":"30","author":"Renzi","year":"1998","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.npep.2016.01.002_bb0495","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI117601","article-title":"Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element","volume":"94","author":"Rozansky","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.npep.2016.01.002_bb0500","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ibd.21403","article-title":"Importance of disrupted intestinal barrier in inflammatory bowel disease","volume":"17","author":"Salim","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0505","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042737-200502000-00012","article-title":"Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY","volume":"17","author":"Schmidt","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.npep.2016.01.002_bb0510","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/en.2004-0051","article-title":"Development and differentiation of gut endocrine cells","volume":"145","author":"Schonhoff","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.npep.2016.01.002_bb0515","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ibd.20851","article-title":"Plasma chromogranin A in patients with inflammatory bowel disease","volume":"15","author":"Sciola","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0520","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbi.2007.08.013","article-title":"Morphological relationships between peptidergic nerve fibers and immunoglobulin A-producing lymphocytes in the mouse intestine","volume":"22","author":"Shibata","year":"2008","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.npep.2016.01.002_bb0525","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1445-2197.1990.tb07434.x","article-title":"Gastrointestinal hormones: from basic science to a clinical perspective","volume":"60","author":"Shulkes","year":"1990","journal-title":"Aust. N. Z. J. Surg."},{"key":"10.1016\/j.npep.2016.01.002_bb0530","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0950-351X(05)80232-0","article-title":"Somatostatin: physiology and clinical applications","volume":"8","author":"Shulkes","year":"1994","journal-title":"Bailliere Clin. Endocrinol. Metab."},{"key":"10.1016\/j.npep.2016.01.002_bb0535","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ibd.20982","article-title":"Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis?","volume":"16","author":"Sidhu","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.npep.2016.01.002_bb0540","first-page":"537","article-title":"Neuroendocrine neoplasms arising in inflammatory bowel disease: a report of 14 cases","volume":"11","author":"Sigel","year":"1998","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.npep.2016.01.002_bb0545","article-title":"Association of serotonin transporter promoter polymorphism (5-HTTLPR) with microscopic colitis and ulcerative colitis","author":"Sikander","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0550","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2249.2009.03956.x","article-title":"Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease","volume":"157","author":"Smalley","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.npep.2016.01.002_bb0555","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0889-8529(18)30136-1","article-title":"The pathology of the gastrointestinal endocrine system","volume":"22","author":"Solcia","year":"1993","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.npep.2016.01.002_bb0560","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3748\/wjg.v11.i13.1987","article-title":"Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits","volume":"11","author":"Spadaro","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.npep.2016.01.002_bb0565","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.crohns.2013.04.019","article-title":"Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity","volume":"7","author":"Strid","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.npep.2016.01.002_bb0570","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2169\/internalmedicine1962.27.49","article-title":"Peptide YY abnormalities in patients with ulcerative colitis","volume":"27","author":"Tari","year":"1988","journal-title":"Jpn. J. Med."},{"key":"10.1016\/j.npep.2016.01.002_bb0575","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.npep.2007.05.002","article-title":"Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry","volume":"41","author":"Ter Beek","year":"2007","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2016.01.002_bb0580","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2007.09.011","article-title":"The role of PYY in feeding regulation","volume":"145","author":"Ueno","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.npep.2016.01.002_bb0585","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10753-013-9612-4","article-title":"Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis","volume":"36","author":"Wagner","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.npep.2016.01.002_bb0590","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.crohns.2012.07.028","article-title":"Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches","volume":"7","author":"Wang","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.npep.2016.01.002_bb0595","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/BF02049408","article-title":"Distribution and quantification of somatostatin in inflammatory disease","volume":"35","author":"Watanabe","year":"1992","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.npep.2016.01.002_bb0600","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2174\/156802607782341046","article-title":"NPY and receptors in immune and inflammatory diseases","volume":"7","author":"Wheway","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.npep.2016.01.002_bb0605","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/BST20150090","article-title":"The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease","volume":"43","author":"Worthington","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.npep.2016.01.002_bb0610","first-page":"175","article-title":"Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages","volume":"30","author":"Wu","year":"2000","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.npep.2016.01.002_bb0615","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02355052","article-title":"Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease","volume":"31","author":"Yamamoto","year":"1996","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.npep.2016.01.002_bb0620","first-page":"161","article-title":"Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease","volume":"20","author":"Yukawa","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.npep.2016.01.002_bb0625","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/00365521.2014.920910","article-title":"Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study","volume":"49","author":"Zissimopoulos","year":"2014","journal-title":"Scand. J. Gastroenterol."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417916000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417916000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T03:36:16Z","timestamp":1748748976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417916000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":127,"alternative-id":["S0143417916000032"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2016.01.002","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chromogranin A and other enteroendocrine markers in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2016.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}